Prenyl functionalities have been widely discovered in
natural products,
nucleic acids, and proteins with significant biological roles in both
healthy and diseased cells. In this work, we develop a series of new
nitroso-based probes for the labeling, enrichment, and regulation
of prenylated RAS protein, which is highly associated with ∼20%
of human cancers and used to be regarded as an “undruggable”
target via a sequential ene-ligation and oxime condensation (SELOC)
process. We found that these nitroso species can rapidly react with
prenyl-containing molecules through ene-ligation and install a molecular
tag for functional applications under physiological conditions. We
first investigated this ligation process on two peptide models and
demonstrated its labeling efficiency on various proteins such as myoglobin,
lysozyme, RNase A, BSA, and HSP40. We further coupled this reactive
platform with proteolysis-targeting chimera technology targeting to
increase its efficiency and accuracy, as well as to expand its application
range. Using the prenylated RAS protein as the model, we demonstrated
that RAS could be efficiently decorated with our nitroso probes, which
further condensate with oxime and rapidly react with a pomalidomide-containing
hydroxylamine probe for protein degradation. As a result, the RAS
protein in both HeLa and A549 cell lines has been determined to be
efficiently degraded both in vitro and in vivo. This is the first
case targeting post-translational modification other than ligand–protein
interaction to degrade and regulate RAS proteins. We envision that
our SELOC strategy will have great potential in studying the fundamental
structures and functions of prenylated biomolecules and developing
new drugs based on these unique cellular pathways.